|
|
|
|
| LEADER |
01766nam a2200313 u 4500 |
| 001 |
EB001839640 |
| 003 |
EBX01000000000000001003629 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 100 |
1 |
|
|a Membe, Stephen K.
|
| 245 |
0 |
0 |
|a Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses
|h Elektronische Ressource
|b an economic analysis and budget impact analysis
|c Stephen K Membe [and five others]
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2011, March 2011
|
| 300 |
|
|
|a 1 PDF file (vii, 27 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Plasma Substitutes / economics
|
| 653 |
|
|
|a Plasma
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Blood Component Transfusion / economics
|
| 653 |
|
|
|a Virus Diseases / transmission
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH technology report
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK298926
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Health Canada recently licensed Octaplas, which can now be considered as an alternative to standard fresh frozen plasma (FFP) for certain indications. Since, on average, 200,000 units of FFP are transfused annually in Canada, the widespread implementation of Octaplas may have significant public health and economic implications. This study investigates the cost-effectiveness position of Octaplas against standard FFP and its budgetary impact to the health care system
|